Aligos Therapeutics Inc (NASDAQ: ALGS) — Company Overview, News & Financial Data
Aligos Therapeutics develops novel therapies for liver diseases, advancing treatment options to improve patient care effectively.
Aligos Therapeutics Inc
Aligos Therapeutics (NASDAQ:ALGS) focuses on developing novel therapeutics that address unmet medical needs in liver diseases, including chronic hepatitis B, NASH (nonalcoholic steatohepatitis), and liver and respiratory diseases caused by coronaviruses. The company dedicates itself to groundbreaking research and the advancement of treatments that can provide significant benefits over existing therapies. Through rigorous scientific investigation and clinical trials, Aligos aims to revolutionize the management and care of patients suffering from these serious conditions. Emphasizing innovation and effectiveness, the company's projects are designed to navigate the complexities of liver diseases and to halt or reverse the progression of illnesses, with the ultimate objective of enhancing the quality of life for patients worldwide.
Snapshot
Operations
Products and/or services of Aligos Therapeutics Inc
- Development of antiviral therapeutics for chronic hepatitis B (CHB) designed to provide a functional cure.
- Research on oligonucleotide platform targeting various RNA-based therapies for liver diseases.
- Innovations in small molecule therapeutics aimed at modulating liver disease pathways.
- Advancement of antiviral drugs for treating respiratory syncytial virus (RSV), offering a new approach to manage infections.
- Collaboration on developing siRNA (small interfering RNA) therapeutics for addressing unmet needs in viral diseases.
- Progression of non-alcoholic steatohepatitis (NASH) treatments, focusing on reducing liver fat and inflammation.
Aligos Therapeutics Inc executive team
- Lawrence M. BlattCEO, President & Chairman of the Board
- Lesley Ann CalhounExecutive VP, CFO & COO
- Julian A. SymonsExecutive VP & Chief Scientific Officer
- Nikhil AnejaPrincipal Accounting Officer
- Laura KavanaughVP & Head of Legal
- Kristina EngesethSenior VP and Head of People & Culture
- Sushmita M. ChandaExecutive Vice President & Chief Development Officer
- David B. SmithExecutive VP & Head of Chemical Operations
- Tse-I LinSenior VP of Early Compound Development & Belgian Site Head
- Kieron WessonVice President & Head of Chemistry Manufacturing Controls
Key financials
Reported results for Aligos Therapeutics Inc, in USD.
- Market cap
- 28.7M
- Revenue (TTM)
- 31.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -7.4
- Dividend yield
- —
- Profit margin
- -241.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.2M | -88M | -24.2M | |
| 3.9M | -89.2M | -131.2M | |
| 15.5M | -88.1M | -87.7M | |
| 13.9M | -97.6M | -96M |